R

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 9, 2023
Webcast, Accounting, Research, Safety, Engineering, Food, Conference call, Risk, Immunodeficiency, Clinical trial, Serum, Cohort study, Abstract, FDA, Research and development, COVID-19, Conference, CDC, R, Antibody, Patent, SARS-CoV-2, Mutation, Pharmaceutical industry, Vaccine, Omicron

ET

Key Points: 
  • ET
    WALTHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) --  Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the quarter ended September 30, 2023, and recent business highlights.
  • “I am immensely proud of our team and their remarkable performance throughout the third quarter.
  • William Duke appointed Chief Financial Officer: On September 5, 2023, Invivyd announced the appointment of William (Bill) Duke as Chief Financial Officer.
  • Third Quarter 2023 Financial Results:
    Cash position: Cash, cash equivalents and marketable securities were $264.9 million as of September 30, 2023.

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023
Paclitaxel, Pancreatic cancer, Safety, DNA, Colorectal cancer, IND, RAS, Administration, Patient, China Bio-Immunity Corporation, Research, RAF, PDAC, Benchmarking, MAPK, Circulating tumor DNA, Binimetinib, Conference, Lung cancer, Melanoma, Cancer, Encorafenib, Toxic oil syndrome, R, Research and development, Immunotherapy, AACR, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency, Immune-related response criteria

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today reported financial results for the third quarter ended September 30, 2023, and provided business updates.

Key Points: 
  • “Completing our Phase 1 dose escalation of IMM-1-104 with no observed dose-limiting toxicities was an important step in that direction.
  • The Phase 2a portion of the study will also include the addition of new sites and investigators focused on these cancer types.
  • Research and Development (R&D) Expenses: R&D expenses for the quarter ended September 30, 2023 were $10.1 million, compared with $9.4 million for the quarter ended September 30, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the quarter ended September 30, 2023 were $3.9 million, compared with $3.8 million for the quarter ended September 30, 2022.

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
R, Investment, RAIN, MANTRA, Research, Cryptocurrency, Rain

NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations.

Key Points: 
  • NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company’s key developments and business operations.
  • “Rain continues to evaluate a number of strategic opportunities to add value for its stockholders,” said Avanish Vellanki, co-founder and chief executive officer of Rain.
  • As of September 30, 2023, Rain had $77.3 million in cash, cash equivalents and short-term investments.
  • As of November 3, 2023, Rain had approximately 36.4 million shares of common stock outstanding.

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Tumor-associated macrophage, Research, Annual general meeting, Renal cell carcinoma, Hereditary diffuse gastric cancer, Head, Colorectal cancer, ESMO, Administration, Patient, Triple-negative breast cancer, ASCO, MSK, FDA, Lung cancer, G&A, Immunotherapy, Patent, ORR, Ovarian cancer, MPH, Cancer, Trial of the century, Diagnosis, Nivolumab, SITC, Operation, Antibody, Research and development, R, Congress, Orphan, Society, TNBC, ISAC, NSCLC, Pharmaceutical industry, Vaccine, Cryptocurrency

Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.

Key Points: 
  • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.
  • Research and Development (R&D) Expenses – R&D expenses were $15.0 million for the quarter ended September 30, 2023, compared to $19.0 million for the same quarter in 2022.
  • General and Administrative (G&A) Expenses – G&A expenses were $5.8 million for the quarter ended September 30, 2023, compared to $5.5 million for the same quarter in 2022.
  • Loss from Operations – Loss from operations was $18.2 million for the quarter ended September 30, 2023, compared to $22.3 million for the same quarter in 2022.

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Thursday, November 9, 2023
CNS, FCAS, Cryopyrin-associated periodic syndrome, Safety, SAN, ALS, Modulation, Psoriasis, Administration, Patient, Research and development, Inflammation, TYK2, Pharmacokinetics, Ulcerative colitis, Blood, Psoriatic arthritis, Multiple sclerosis, R, NLRP3, Phase II, Volunteering, UC, Peripheral, Cryptocurrency, Pharmaceutical industry, CAPS

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent pipeline and business progress.

Key Points: 
  • Accordingly, we have elected to terminate ongoing activities in the Phase 2 trials of VTX958 in plaque psoriasis and psoriatic arthritis.
  • Research and Development (R&D) expenses: R&D expenses were $49.8 million for the quarter ended September 30, 2023, compared to $25.5 million for the quarter ended September 30, 2022.
  • General and Administrative (G&A) expenses: G&A expenses were $8.2 million for the quarter ended September 30, 2023, compared to $6.0 million for the quarter ended September 30, 2023.
  • Net loss: Net loss was $54.0 million for the quarter ended September 30, 2023, compared to $30.5 million for the quarter ended September 30, 2022.

Applied Molecular Transport Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
NDA, Workforce, G&A, R, Research, AMTI, AMT, Cryptocurrency

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Cash and Cash Equivalents of $18.1 million, as of September 30, 2023
    SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023.
  • Total R&D expenses for the third quarter of 2023 were $0.3 million, compared to $18.2 million for the same period in 2022.
  • Total G&A expenses for the third quarter of 2023 were $7.0 million, compared to $7.3 million for the same period in 2022.
  • Net loss for the third quarter of 2023 was $6.9 million, compared to $25.2 million for the same period in 2022.

Webscale Network Operators: Surge in Generative AI Investments Highlights Growth Trajectories in Q3 2023 Market Review - ResearchAndMarkets.com

Retrieved on: 
Monday, December 18, 2023
Technology, Networks, Internet, Artificial Intelligence, Research, R&D, Employment, Yoy, Amazon, WNO, Investment, Public expenditure, R, Growth, AI, Microsoft, Meta, Renewable energy

The global webscale network operator (WNO) market has demonstrated notable resilience and growth, according to the latest market review focusing on developments since 2011.

Key Points: 
  • The global webscale network operator (WNO) market has demonstrated notable resilience and growth, according to the latest market review focusing on developments since 2011.
  • The review reveals that webscalers have amassed a remarkable $2.32 trillion in revenues, marking a 3.7% year-over-year (YoY) increase.
  • The report also highlights the steady increase in cash and short-term investments, evidencing the financial fortitude of major players.
  • The market landscape has evolved dramatically over the past decade, with webscale capex challenging the supremacy of traditional telecom investments.

Generative AI in the Chemicals and Materials Industry Report 2023: Technology Advances and Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, December 18, 2023
Technology, Chemicals, Plastics, Artificial Intelligence, Manufacturing, R, Machine learning, Gen, Research, Data science, Chemical substance, Medical device

The "Generative AI in the Chemicals and Materials Industry: Technology Advances and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Generative AI in the Chemicals and Materials Industry: Technology Advances and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • Generative artificial intelligence (GenAI) is emerging as a game changer in the chemicals and materials industry.
  • This research service identifies the pain points across various business functions in the chemicals and materials industry, determining how they can be addressed by harnessing Gen AI.
  • The study also examines the investment landscape, identifies the key industrial and academic players in this space, and highlights growth opportunities enabling the development and adoption of Gen AI technology in the chemicals and materials industry.

United States Connected Drug Delivery Devices Markets, Competition, Forecasts & Opportunities, 2028F - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Health, Pharmaceutical, Senior counsel, ClinicalTrials.gov, Hepatitis C, COPD, Hypertension, Research, Chronic obstructive pulmonary disease, Conditional sentence, Healthcare Facilities Accreditation Program, Asthma, Dexcom, Patient, Male, Administration, Roche, R, Growth, Hospital, Female, Diabetes, Pharmacotherapy, Tuberculosis, Pharmaceutical industry, Birth control

Improvement in the quality of patient care and compliance and the changing healthcare infrastructure is expected to boost the United States connected drug delivery devices market growth.

Key Points: 
  • Improvement in the quality of patient care and compliance and the changing healthcare infrastructure is expected to boost the United States connected drug delivery devices market growth.
  • The segment is anticipated to dominate the United States connected drug delivery devices market in the next five years.
  • Also, the awareness regarding the benefits of connected systems over the traditional drug delivery system with improved patient response is expected to accelerate the growth of the United States connected drug delivery devices market.
  • Company Profiles: Detailed analysis of the major companies present in the United States connected drug delivery devices market.

Generational Equity Advises R&F Industries in its Sale to Candler Industries

Retrieved on: 
Thursday, December 14, 2023
Other Manufacturing, Environment, Consulting, Engineering, Chemicals, Plastics, Professional Services, Manufacturing, Other Natural Resources, Mining, Minerals, Natural Resources, Sale, R&F, Equity, Marketing, M&A, Lubricant, Solvent, R

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client R&F Industries, Inc. to Candler Industries, Inc.

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client R&F Industries, Inc. to Candler Industries, Inc.
  • R&F Industries, Inc. (R&F), located in Luling, Texas, is dedicated to the development, manufacturing, and marketing of specialty chemicals for the drilling and mining industries.
  • Generational Equity Executive Managing Director of M&A – Central Region, Michael Goss , and his team led by Vice President, M&A, Jacob Mangalath successfully closed the deal.
  • “We are so blessed and happy that R&F Industries found the perfect buyer in Candler Industries.